1-5 of 5
Tamas Masszi, MD Prof.
Close
Sort by
Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Jean-Jacques Kiladjian, MD PhD, Pierre Zachée, Masayuki Hino, MDPhD, Fabrizio Pane, Tamas Masszi, MD Prof., Claire N. Harrison, MD DM, FRCP, PRCPath, Ruben A. Mesa, MD, Carole B. Miller, MD, Francesco Passamonti, MD, Simon Durrant, FRCP,FRCPath,MBBS, Martin Griesshammer, MD PhD, Keita Kirito, MD, Carles Besses, MD PhD, Beatriz Moiraghi, Elisa Rumi, MD, Vittorio Rosti, MD, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1753.
https://doi.org/10.1182/blood-2018-99-115129
Published: 2018
Journal Articles

Real World Data on the Efficacy and Safety of Daratumumab in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Hematology Centers

Gergely Varga, PhD, Tamas Masszi, MD Prof., Péter Farkas, MD, Nikolett Wohner, PhD, Ágnes Bereczki, MD, Zita Borbenyi, MD, Árpád Szomor, MD PhD, Hussain Alizadeh, MD PhD DSc, Erika Szaleczky, PhD, Krisztina Wolf, MD, Tamás Schneider, MD PhD, Mark Plander, PhD, Tamás Szendrei, MD, László Váróczy, MD PhD, Árpád Illés, Ottó Csacsovszky, MD, Zoltán Csukly, MD, Miklos Egyed, MD PhD, Péter Rajnics, PhD, Nora Adamkovich, MD, Szabolcs Kosztolányi, MD, Gábor Mikala, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3257.
https://doi.org/10.1182/blood-2018-99-115039
Published: 2018
Journal Articles

Description of the First Cases with ADAMTS13 Mutations in Hungary

Marienn Réti, MD, György Sinkovits, MD, Orsolya Cseprekál, MD PhD, Dorottya Csuka, PhD, Ágnes Szilágyi, PhD, Zita Farkas, MD, Zsolt Klucsik, MD, Attila Szederjesi, MSC, László Wágner, MD Prof, György Reusz, MD Prof, Johanna A. Kremer Hovinga, MD Prof, János Rigó, MD Prof, Tamas Masszi, MD Prof., Zoltan Prohászka, MD Prof
Journal: Blood
Blood (2018) 132 (Supplement 1): 5003.
https://doi.org/10.1182/blood-2018-99-118327
Published: 2018
Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Jean-Jacques Kiladjian, MD PhD, Srdan Verstovsek, MD PhD, Martin Griesshammer, Tamás Masszi, MD Prof., Simon Durrant, FRCP,FRCPath,MBBS, Francesco Passamonti, MD, Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Keita Kirito, MD, Carlos Besses, MD PhD, Masayuki Hino, MDPhD, Ana Ines Varela, Carole B. Miller, MD, Elisa Rumi, MD, Vittorio Rosti, MD, Igor Wolfgang Blau, MD, Ruben A Mesa, MD, Tuochuan Dong, Nathalie Francillard, Mary Laughlin, Alessandro M. Vannucchi
Journal: Blood
Blood (2017) 130 (Supplement 1): 322.
https://doi.org/10.1182/blood.V130.Suppl_1.322.322
Published: 2017
Journal Articles

Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Dietrich W Beelen, MD PhD, Rudolf Trenschel, MD, Matthias Stelljes, MD, Tamás Masszi, MD Prof., Péter Reményi, Eva-Maria Maria Wagner-Drouet, MD, Peter Dreger, MD Prof., Wolfgang Bethge, MD Prof., Fabio Ciceri, MD, Friedrich Stoelzel, MD, Christian Junghanss, MD, Mauricette Michallet, MD Prof., Miroslaw Markiewicz, MD Prof.
Journal: Blood
Blood (2017) 130 (Supplement 1): 521.
https://doi.org/10.1182/blood.V130.Suppl_1.521.521
Published: 2017